Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.


Autoria(s): Buchegger F.; Press O.W.
Data(s)

2011

Resumo

ABSTRACT: Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy (RIT) consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of these two interventions are currently under discussion. We now raise the question whether both RIT consolidation and rituximab maintenance should be used together aiming to augment the results achievable with R-chemotherapy.

Identificador

https://serval.unil.ch/?id=serval:BIB_12A813318318

isbn:2191-219X (Electronic)

pmid:22214546

doi:10.1186/2191-219X-1-7

isiid:000209435600007

http://my.unil.ch/serval/document/BIB_12A813318318.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_12A8133183180

Idioma(s)

en

Direitos

info:eu-repo/semantics/openAccess

Fonte

EJNMMI Research, vol. 1, no. 1, pp. 7

Tipo

info:eu-repo/semantics/article

article